Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Earnings

BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026

By The Northwire Desk — AI Analysis Mar 12, 2026 · 17:30 RX · 15.7 BioSyent Inc.
RX · Price

Executive Summary

  • BioSyent Inc. will release its Q4 2025 and full‑year 2025 financial results on Thursday, March 19, 2026 after market hours.
  • A presentation of the results by President & CEO René Goehrum will be posted on the Company’s website concurrent with the release.

Key Details

  • Announcement date: March 12, 2026 (Globe Newswire).
  • Reporting period: Fourth quarter and full year ended December 31, 2025.
  • Release schedule: Results to be disclosed after market close on March 19, 2026.
  • Presentation: CEO René Goehrum will provide a slide deck covering the Q4 and FY 2025 results; it will be available on BioSyent’s website on the same day.
  • Contact for investors: René C. Goehrum, President & CEO – email [email protected], phone 905‑206‑0013.

Notable Quotes

(No quotes were included in the release.)

Read the original news release →

More from BioSyent Inc.

May 19, 2026 · 09:52

BioSyent enters endocrinology with sole-source liquid levothyroxine — a niche launch, but the upside hinges on Tibella/FeraMAX still doing the heavy lifting.

Regulatory May 14, 2026 · 18:00

BioSyent’s Q1 Shows Oral Science Deal Paying Off, but Pharma Core Holds Steady

Earnings Mar 19, 2026 · 17:30

BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

Earnings Mar 02, 2026 · 21:07

BioSyent closes Oral Science acquisition, grants RSUs

M&A / Property Mar 02, 2026 · 08:30

BioSyent Announces Closing of the Acquisition of Oral Science Inc.

M&A / Property Feb 09, 2026 · 17:54

BioSyent to acquire Oral Science for $25.5-million

M&A / Property